Pharmacokinetics, Pharmacodynamics and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Cov...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacol Ther
Autori principali: Kim, Hanna, Brooks, Kristina M., Tang, Cheng Cai, Wakim, Paul, Blake, Mary, Brooks, Stephen R., Sanchez, Gina A. Montealegre, de Jesus, Adriana A., Huang, Yan, Tsai, Wanxia Li, Gadina, Massimo, Prakash, Apurva, Janes, Jonathan Marcus, Zhang, Xin, Macias, William L., Kumar, Parag, Goldbach-Mansky, Raphaela
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089664/
https://ncbi.nlm.nih.gov/pubmed/29134648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.936
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi